Bill Sibold, Chief Executive Officer of Madrigal, stated “As we approach the March PDUFA date for resmetirom, we remain focused on advancing key regulatory, operational and commercial activities in preparation for a potential U.S. launch. Our goal is to establish resmetirom as the foundational therapy for NASH with significant fibrosis, a serious disease with significant unmet need that represents a high burden to patients, their families and the healthcare system.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
- Madrigal opportunity in MASH remains after Boehringer data, says UBS
- Madrigal Pharmaceuticals downgraded to Sell at B. Riley after competitor data
- Madrigal Pharmaceuticals downgraded to Sell from Neutral at B. Riley
